I agree, several years back the price hit a high of $9.90 with lower revenue stream and lower profit, here we are with higher revenue stream and higher profit and getting a lower price for the company.
Look at DTRK which is being bought by the CEO in the open market for pennies with no disclosure to the public except the current shareholders once a year. Whatever happened to fiduciary duty to shareholders who have been loyal to a company with no reward after a long recovery . MDSO trades with a market cap of 1 Billion dollars with similar growth. Maybe the SEC needs to look at all the self dealing of BIOC and DTRK